Although numerous studies have shown that IL‐17A and its downstream signaling contribute to poor prognosis in several cancers, including osteosarcoma, NSCLC gastric cancer, pancreatic carcinoma and CRC,4, 10, 15, 16, 20 the role of IL‐17RA in tumor development and progression remains unclear. This evidence concerns the gene IL17A and exocrine pancreatic carcinoma.